<DOC>
	<DOCNO>NCT01433003</DOCNO>
	<brief_summary>Thrombotic thrombocytopenia purpura / hemolytic uremic syndrome ( TTP/HUS ) rare , life-threatening disorder . TTP/HUS cause multiple blood clot form , prevents blood reach brain kidney . TTP/HUS affect 3-5 people per million per year . Anyone develop TTP/HUS , common among 30-40 year old , woman twice likely men acquire condition . TTP/HUS sometimes develop result medication use , pregnancy cancer ; however , majority patient ( 80 % ) cause TTP/HUS unknown . In 1991 , researcher discover plasma exchange superior plasma infusion treat idiopathic TTP/HUS . During plasma exchange patient 's blood plasma remove replace healthy blood plasma . Without plasma exchange , survival rate TTP/HUS extremely low , few 5 % patient survive . Treating TTP/HUS plasma exchange improve survival rate 80 % . Although represent dramatic improvement , researcher still search method improve survival . No major advance treat TTP/HUS occur past 20 year . Recent research suggest high-dose plasma exchange may improve survival TTP/HUS patient . The investigator conduct randomize controlled trial test whether treat TTP/HUS patient high-dose versus standard-dose plasma exchange improve treatment response . The investigator recruit 150 patient TTP/HUS 9 centre across Canada three year . The investigator evaluate whether high-dose plasma exchange improve treatment response , survival , whether reduces number volume plasma exchange procedure duration hospital stay .</brief_summary>
	<brief_title>The Plasma Large-Volume Exchange RCT</brief_title>
	<detailed_description>Background : Thrombotic thrombocytopenia purpura / haemolytic uremic syndrome ( TTP/HUS ) rare blood disorder high mortality rate &gt; 95 % leave untreated . In 1991 , researcher discover treat TTP/HUS plasma exchange vs. plasma infusion dramatically improve survival rate , 60 % 80 % .The optimal plasma dose treat TTP/HUS unknown ; however , recent research suggest high-dose plasma exchange may improve survival patient TTP/HUS . Hypothesis : Treatment TTP/HUS high-dose vs. standard-dose plasma exchange significantly decrease composite outcome 1 ) treatment failure day 5 and/or 2 ) non-response death 2 week . Methods : The investigator conduct multi-centre , parallel group randomize control trial . The investigator anticipate recruit 150 eligible patient idiopathic TTP/HUS 9 centre across Canada 2.25 year . Patients randomized receive high-dose plasma exchange ( 125 ml/kg/day 10 L/day plasma volume ) standard-dose plasma exchange ( 50-75 ml/kg/day ; approximately 1-1.5 plasma volume ) . The primary composite outcome include treatment failure day 5 non-response death cause 2 week . Secondary outcome include individual component primary outcome , non-response death cause month 1 month 6 , day remission , duration hospital stay , number volume plasma exchange treatment , cost minimization . Research Team : Our multi-centre team part Canadian Apheresis Group , establish 1980 currently operate 30 centre across Canada . Collectively , Canadian Apheresis Group treat 150 TTP/HUS patient year . Our team include experienced haematologist , nephrologists , epidemiologist biostatistician . The investigator successfully collaborate several project excellent publication record ( &gt; 50 publication across 15 journal include New England Journal Medicine ) . Timeline Budget : Because TTP/HUS relatively rare disorder ( orphan disease ) , investigator recruit patient 2.25 year across Canada achieve sufficiently large sample size . A cost minimization study carry conjunction RCT provide insight potential costing . Future Directions : If investigator demonstrate high-dose plasma exchange significantly improve primary outcome , investigator pursue multi-national collaboration American , Chinese European Centres investigate important outcome include optimal dosing , cost-effectiveness survival . Implications : This study potential first major advancement treat TTP/HUS twenty year .</detailed_description>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1 . Age &gt; 18 yearold 2 . First presentation TTP/HUS 3 . Meet follow diagnostic criterion : Platelet count &lt; 150 x 109 /L Microangiopathic haemolytic anaemia ( blood film presence red blood cell fragmentation ) LDH &gt; 1.25 X upper limit normal No alternative diagnosis 1 . Secondary TTP/HUS 2 . Relapsing TTP/HUS 3 . Hypersensitivity blood product 4 . Patient receive 2 plasma exchange treatment since symptom start last 1 week 5 . Received medication , include cyclosporine , cyclophosphamide , rituximab treatment TTP/HUS 6 . Other cause thrombocytopenia TTP/HUS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Thrombotic thrombocytopenia purpura</keyword>
	<keyword>hemolytic uremic syndrome</keyword>
	<keyword>plasma exchange</keyword>
	<keyword>Improve treatment response</keyword>
	<keyword>TTP/HUS</keyword>
</DOC>